Descovy to help Gilead maintain dominance of HIV market?

GlobalData's most recent HIV report says that the market will see major shifts in the types of treatments administered to patients in the next few years

mq1

The recent FDA approval of Gilead Sciences' drug Descovy (emtricitabine/tenofovir alafenamide [TAF]) in the treatment of human immunodeficiency virus (HIV) will boost the company's TAF-based HIV portfolio, and allow Gilead to stay on top of a fast-changing treatment landscape, according to an analyst with research and consulting firm GlobalData.

GlobalData's most recent HIV report says that the market will see major shifts in the types of treatments administered to patients in the next few years.

Indeed, fixed-dosed combinations (FDCs) and single-tablet regimens (STRs) are transforming the HIV landscape, and tenofovir disoproxil fumarate (TDF) treatments are beginning to be challenged by clinically superior TAF-based therapies.

Mr David Fratoni, MSc, GlobalData's Analyst covering Infectious Diseases, explains: "The launch of Descovy means Gilead is now responsible for bringing three TAFs to the US market in less than six months, including Genvoya (elvitegravir/cobicistat/emtricitabine/TAF) and Odefsey (emtricitabine/rilpivirine/TAF). This commitment to building a strong TAF profile represents a remarkable milestone for Gilead's fight against HIV, cementing its leading position in the arena for now.

"Such a strategy comes at an opportune time for the company, as it encounters the rise of generic HIV regimens and branded FDCs and STRs. In fact, Gilead will have to face US and/or EU patent expirations of two of its TDF-based HIV therapies, Viread (TDF) and Truvada (emtricitabine/TDF), beginning in 2017, which will stimulate the entry of multi-tablet regimens from various generics manufacturers."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X